The active-quant buying cluster (D.E. Shaw, Jane Street, RenTech, Point72, Bridgewater) is a strong signal that sophisticated investors are positioning for the upcoming PDUFA catalysts (BBP-418 Nov 2026, encaleret May 2027). The passive selling is likely index-rebalancing noise. Monitor for any insider buying to corroborate the thesis, current insider activity shows 7 sells in the last 30 days with no open-market buys, which is a divergence. The $1B preferred equity financing provides a cash runway through these catalysts.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 24 $81.07entry
- T+1 · 3mo ago −0.83%α −1.15% · $80.40
- T+5 · 3mo ago −5.53%α −6.00% · $76.59
- T+20 · 8w ago −14.60%α −15.92% · $69.23
- T+59 · todayOpen
- T+60 · in 12h Pending
How similar events traded
Executive Summary
BridgeBio Pharma saw a mixed institutional cluster in Q2 2026, with 33 buyers adding $561.6M in net new positions (led by Norges Bank, Point72, and D.E. Shaw) while 25 sellers trimmed $218.2M (led by Geode and Northern Trust). The buying is concentrated among active quant and asset managers (D.E. Shaw, Jane Street, RenTech, Point72) likely positioning ahead of key PDUFA catalysts (BBP-418 Nov 2026, encaleret May 2027) and the $1B preferred equity financing, while the selling is dominated by mega-passive index funds (Geode, T. Rowe Price) trimming for rebalancing. The divergence between active buyers and passive sellers, combined with the strong Q2 revenue growth ($243.7M, more than doubling YoY) and the recent $1B capital raise, suggests conviction in the pipeline catalysts outweighs the EPS miss and ongoing operating losses.
Key Financial Metrics
Institutional Positions
Net institutional flow: $343.4M
▲ Buyers (33)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Norges Bank | NEW | +100% | $126.2M | $126.2M |
| Point72 | NEW | +100% | $113.6M | $113.6M |
| D.E. Shaw | ADD | +42.7% | $270.6M | $81.6M |
| Jane Street Group | ADD | +66.9% | $218.5M | $88.0M |
| RenTech | DOUBLED | +134.3% | $63.8M | $36.7M |
▼ Sellers (25)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Geode | TRIM | -30.5% | $371.9M | -$117.3M |
| Northern Trust | TRIM | -31.6% | $104.2M | -$32.8M |
| American Century Companies | TRIM | -43% | $81.0M | -$34.7M |
| Walleye Capital | NEAR_EXIT | -99.3% | $17.0M | -$16.9M |
| T. Rowe Price | TRIM | -54.6% | $282.0K | -$153.7K |
Key Facts
- 33 institutional buyers added $561.6M in net new positions in Q2 2026
- 25 institutional sellers trimmed $218.2M, led by mega-passive index funds
- Norges Bank initiated a new $126.2M position; Point72 initiated $113.6M
- D.E. Shaw added $81.6M (+42.7%), Jane Street added $88.0M (+66.9%)
- Geode trimmed $117.3M (-30.5%), Northern Trust trimmed $32.8M (-31.6%)
- Q2 2026 revenue $243.7M (more than doubled YoY) but EPS missed consensus ($0.78 actual vs $0.64 consensus)
- Key catalysts: BBP-418 PDUFA Nov 27, 2026; encaleret PDUFA May 8, 2027
- $1B preferred equity financing completed post-quarter
Financial Impact
Net institutional buying of $561.6M by 33 buyers vs $218.2M selling by 25 sellers, for a net inflow of approximately $343.4M in Q2 2026
Risk Factors
- EPS miss of $0.78 vs $0.64 consensus indicates ongoing profitability challenges
- No insider open-market buying to corroborate the institutional thesis
- PDUFA catalysts are binary events with significant downside risk on failure
- 13F data is 45+ days stale; positions may have been adjusted since quarter-end
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-BBIO-2026-Q2 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers